Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

I Leader della Finanza

Ultime notizieSocietÓMercatiEconomia & ForexMaterie PrimeTassiLeader della FinanzaPro. della FinanzaAgendaSettori 
HomeTutte le notizieLe notizie pi¨ letteBiografie dei Leader della finanza
Riassunto 
Founder of Clinical Regulatory Services LLC, Claude Nicaise currently is Head-Research & Development at Ovid Therapeutics, Inc. Dr. Nicaise is also on the board of Sarepta Therapeutics, Inc., Minoryx Therapeutics SL, Gain Therapeutics, Inc. and Chemomab Therapeutics Ltd. and Member of American Society of Clinical Oncology, Member of American Society of Hematology, Member of American Society for Microbiology, Member of European Society for Medical Oncology and Owner at Clinical Regulatory Services LLC.

In his past career Claude Nicaise held the position of Deputy Medical Officer at Outlook Therapeutics, Inc., Vice President-Global Development at Bristol Myers Squibb Co., Senior Vice President-Global Regulatory Affairs at Alexion Pharmaceuticals, Inc. and VP-Clinical Development & Regulatory Affairs at Formula Pharmaceuticals, Inc.

Claude Nicaise received a doctorate from UniversitÚ Libre de Bruxelles.


Posti e reponsabilitÓ di Claude Nicaise 
NomeTitolo Da
Sarepta Therapeutics, Inc.
(Biotecnologia)
Independent Director 2015
Ovid Therapeutics Inc.
(Biotecnologia)
Head-Research & Development 2021
Gain Therapeutics, Inc.
(Biotecnologia)
Independent Director 2021
Chemomab Therapeutics Ltd.
(Biotecnologia)
Independent Director 2021
Minoryx Therapeutics SL Independent Director -
American Society of Clinical Oncology Member -
American Society of Hematology Member -
American Society for Microbiology Member -
European Society for Medical Oncology Member -
Clinical Regulatory Services LLC Owner 2014


Participazioni di Claude Nicaise 
NomeAzioni%Valorizzazione
Sarepta Therapeutics, Inc. (SRPT)
(Biotecnologia)
9 1260,011%712 923 USD
Chemomab Therapeutics Ltd.00,0000%0 USD


Claude Nicaise: network personale 
Le notizie pi¨ lette 
15/09BRAD SMITH: Microsoft annuncia il riacquisto di azioni fino a 60 miliardi di dollari e aumenta il dividendo
MR
13/09MARTIN SORRELL: S4 Capital di Sorrell alza le prospettive di profitto al 40%
MR
14/09STEPHEN SCHERR: Goldman Sachs nomina Coleman come nuovo CFO, sostituendo Scherr
MR
08/09MICHAEL O'LEARY: Ryanair, aeroporti britannici in difficoltà a Natale - O'Leary
RE
09/09FRANCESCO GAETANO CALTAGIRONE: Generali, Caltagirone arrotonda quota a 6,1%
RE
17/09LEONARDO DEL VECCHIO: Generali, Caltagirone e Del Vecchio cercano alleati, non vogliono Opa
RE
15/09FRANCESCO GAETANO CALTAGIRONE: Generali, Caltagirone aumenta quota di ulteriore 0,11%, sale sopra 6%
RE
14/09VINCENT BOLLORÉ: Bolloré avrà quota Universal da 5,9 mld euro dopo quotazione
RE
Pi¨ notizie


© 2021 People and Ownership :   
Claude Nicaise : connessioni